Sameem M. Abedin

Sameem M. Abedin

Hematology | Oncology
8800 W. Doyne Ave.
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Journal: Leukemia & lymphoma
Published: July 29, 2026

From Static to Dynamic - Refining MDS Risk through Clonal Evolution.

From Static to Dynamic - Refining MDS Risk through Clonal Evolution.

Journal: NEJM evidence
Published: May 26, 2026

Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

Journal: Transplantation and cellular therapy
Published: April 29, 2026

TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Journal: Blood advances
Published: November 12, 2025

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Journal: Blood advances
Published: November 12, 2025

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia
Published: January 22, 2025

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.

Journal: Blood advances
Published: January 21, 2025

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.

Journal: Blood
Published: December 20, 2024

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Journal: Leukemia
Published: October 31, 2024

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.

Journal: Blood advances
Published: August 27, 2024

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.

Journal: Current hematologic malignancy reports
Published: August 02, 2024

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment.

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment.

Journal: Blood
Published: July 15, 2024
Showing 1-12 of 58

Last Updated: 09/26/2026